cancer of unknown primary
Canhelp Genomics Partners With Mirxes Singapore to Offer Tumor Origin Identification Testing
The firms will make the Canhelp-Origin tumor identification test available for patients with cancers of unknown origin in some Southeast Asian countries.
New Data Shore Up Evidence for Paired Tumor Origin, Molecular Testing in Cancer of Unknown Primary
Premium
Biotheranostics' CancerType ID can predict tumor origins for the majority of CUP patients, with reflex biomarker testing finding those eligible for targeted treatment.
Genomic Profiling Aids Patients With Cancers of Unknown Primary in Trial, Though Benefit is Limited
In the CUPISCO trial, molecularly guided treatment reduced the risk of progression or death by 28 percent compared to patients receiving chemotherapy.
Canhelp Genomics Secures NMPA Approval for Pan-Cancer Tissue-Origin Assay, Analysis Software
The Canhelp-Origin Test measures the gene expression pattern of 90 specific markers of tissue samples and classifies 21 major tumor types.
AI-Based Pathology Method Developed to Potentially Uncover Cancers of Unknown Primary Origin
Premium
In a paper published in Nature, Brigham and Women's researchers describe a novel computational pathology method to improve diagnosis and treatment of metastatic cancers.